SAN DIEGO – February 19, 2013 — OncoSec Medical Inc. (OTCBB: ONCS), a company developing its advanced-stage ImmunoPulse DNA-based immunotherapy and NeoPulse therapy to treat solid tumor cancers, announced that Vice President and Controller, Veronica Vallejo has been promoted to Chief Financial Officer effective February 8, 2013.
“Veronica has been an integral part of our team since the inception of OncoSec and this promotion is well deserved. Her strategic insights and strong financial acumen will be valuable to the future success and growth of the company,” said Punit Dhillon, President and CEO.
Veronica has over fifteen years of public accounting experience and has worked for nearly a decade in a senior management position. She has extensive experience in public company operations and all financing and accounting functions. Veronica holds a B.S. in Business Administration with an emphasis in accounting from San Diego State University. She is a certified public accountant and a member of the American Institute of Certified Public Accountants.